Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 83,900 shares, a growth of 20.2% from the April 15th total of 69,800 shares. Based on an average trading volume of 1,006,700 shares, the days-to-cover ratio is presently 0.1 days.
Astellas Pharma Stock Performance
Shares of ALPMY stock traded up $0.12 during mid-day trading on Tuesday, reaching $9.74. The stock had a trading volume of 444,655 shares, compared to its average volume of 300,689. Astellas Pharma has a one year low of $9.15 and a one year high of $16.91. The firm has a market cap of $17.63 billion, a PE ratio of 137.43, a P/E/G ratio of 1.69 and a beta of 0.37. The firm's 50 day simple moving average is $10.27 and its 200 day simple moving average is $11.18. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.31.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.11 earnings per share (EPS) for the quarter. The company had revenue of $2.79 billion during the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. On average, analysts forecast that Astellas Pharma will post 0.44 EPS for the current year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
